Tags

Type your tag names separated by a space and hit enter

Pharmacokinetics of buspirone in autistic children.
J Clin Pharmacol 2006; 46(5):508-14JC

Abstract

Buspirone is used to treat generalized anxiety disorder in children and may be useful in developmental disorders in which brain serotonin synthesis is altered. Autistic children (13 boys, 7 girls) were given a single oral dose of 2.5 mg (2-3 years) or 5.0 mg (4-6 years). Blood was collected for 8 hours, and plasma was assayed for buspirone and its metabolite 1-pyrimidinylpiperazine (1-PP). The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours. Half-life was 1.6 +/- 0.3 hours. Peak concentrations of 1-PP were 4.5-fold higher than for buspirone. Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio. These results suggest that buspirone is rapidly absorbed and eliminated in young children with extensive metabolism to 1-PP. Plasma concentrations with 2.5- to 5.0-mg doses were similar to those observed in older children receiving 7.5- to 15-mg doses.

Authors+Show Affiliations

Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA. dje@wayne.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16638734

Citation

Edwards, David J., et al. "Pharmacokinetics of Buspirone in Autistic Children." Journal of Clinical Pharmacology, vol. 46, no. 5, 2006, pp. 508-14.
Edwards DJ, Chugani DC, Chugani HT, et al. Pharmacokinetics of buspirone in autistic children. J Clin Pharmacol. 2006;46(5):508-14.
Edwards, D. J., Chugani, D. C., Chugani, H. T., Chehab, J., Malian, M., & Aranda, J. V. (2006). Pharmacokinetics of buspirone in autistic children. Journal of Clinical Pharmacology, 46(5), pp. 508-14.
Edwards DJ, et al. Pharmacokinetics of Buspirone in Autistic Children. J Clin Pharmacol. 2006;46(5):508-14. PubMed PMID: 16638734.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetics of buspirone in autistic children. AU - Edwards,David J, AU - Chugani,Diane C, AU - Chugani,Harry T, AU - Chehab,Jamal, AU - Malian,Monica, AU - Aranda,Jacob V, PY - 2006/4/28/pubmed PY - 2006/12/13/medline PY - 2006/4/28/entrez SP - 508 EP - 14 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 46 IS - 5 N2 - Buspirone is used to treat generalized anxiety disorder in children and may be useful in developmental disorders in which brain serotonin synthesis is altered. Autistic children (13 boys, 7 girls) were given a single oral dose of 2.5 mg (2-3 years) or 5.0 mg (4-6 years). Blood was collected for 8 hours, and plasma was assayed for buspirone and its metabolite 1-pyrimidinylpiperazine (1-PP). The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours. Half-life was 1.6 +/- 0.3 hours. Peak concentrations of 1-PP were 4.5-fold higher than for buspirone. Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio. These results suggest that buspirone is rapidly absorbed and eliminated in young children with extensive metabolism to 1-PP. Plasma concentrations with 2.5- to 5.0-mg doses were similar to those observed in older children receiving 7.5- to 15-mg doses. SN - 0091-2700 UR - https://www.unboundmedicine.com/medline/citation/16638734/Pharmacokinetics_of_buspirone_in_autistic_children_ L2 - https://doi.org/10.1177/0091270006286903 DB - PRIME DP - Unbound Medicine ER -